Fundraising Fox
🦊/People
Sign in

Bali Muralidhar

Investor

Managing Partner at Abingworth · Non Executive Director at British Business Investments · Board director at AdvanCell · Board director at Wugen · Board director at Spruce Biosciences

London

Writes $15M – $30M checks · typically $22.5M

Find your path to Bali

874 people in our graph share verified history with Bali — schools, employers, funds. One of them is your warm intro.

Hannah SealunlockedBali: together at University of Cambridge (2006–2008)
×7Bali: together at University of Cambridge
×2Bali: together at University of Oxford
Bali: together at Bain Capital

About

Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.

Contact· self-published, not guessed

Invests in

BiotechHealthtech

Board director at AdvanCell

Intro paths

→

In turn, Bali can intro founders to AdvanCell's investors below.

AdvanCell's investors · 9

AbingworthLondon · $15M – $30M checks · since 2026Ally Bridge GroupNew York · since 2026Bain Capital Life SciencesBoston · since 2026Catalio Capital Management, LPNew York · since 2026Proto AxiomSydney · since 2026Sanofi VenturesCambridge · $5M checks · since 2026SV Health InvestorsBoston · $1M – $20M checks · since 2026T. Rowe PriceBaltimore · since 2026Tenmilesince 2026

Co-founders at AdvanCell

AAAndrew Adamovich
Andrew AdamovichDirector

Board director at Wugen

Intro paths

→

In turn, Bali can intro founders to Wugen's investors below.

Wugen's investors · 8

AbingworthLondon · $15M – $30M checks · since 2020Aisling CapitalNew York · since 2025Alpha Wave GlobalMiamiBioGenerator VenturesSt. Louis · $50K – $250K checksFidelity InvestmentsBoston · since 2025Intermediate Capital GroupLondon · $5M – $50M checks · since 2025LYZZ CapitalShanghai · since 2025RiverVest Venture PartnersSt. Louis · $500K – $3M checks · since 2021

Board director at Spruce Biosciences

Intro paths

→

In turn, Bali can intro founders to Spruce Biosciences's investors below.

Spruce Biosciences's investors · 8

AbingworthLondon · $15M – $30M checks · since 2025Aisling CapitalNew YorkHealthCapStockholm · since 2020Norwest Venture PartnersMenlo Park · $10M – $30M checks · since 2025Novo HoldingsCopenhagen · $1.1M – $54M checksOmega FundsBostonOrbiMedNew York · $1M – $75M checks · since 2020RiverVest Venture PartnersSt. Louis · $500K – $3M checks · since 2020

Experience

  1. AbingworthGlobal Head of Life Sciencescurrent2026 — present
  2. AbingworthManaging Partner, Chief Investment Officercurrent2022 — present
  3. AbingworthManaging Partnercurrent2020 — presentLondon, United Kingdom
  4. AbingworthPartner2019 — 2020
  5. British Business BankNon Executive Directorcurrent2025 — presentLondon, United Kingdom
  6. MVM PartnersPartner2012 — 2019London, United Kingdom
  7. Bain CapitalAssociate2011 — 2012
  8. Bain & CompanyConsultant2008 — 2011
  9. University of Cambridge, Downing CollegeBye-Fellow2006 — 2008
  10. Medical Reseach CouncilResearcher2005 — 2008Translational Cancer Cell Unit - Cambridge University
  11. National Health ServiceClinical Fellow2004 — 2008Cambridge, United Kingdom

Skills & more

Strategy10Venture Capital34Private Equity14Healthcare13Biotechnology21Molecular Biology2Medicine4Cancer6Lifesciences5Business Strategy11Due Diligence9Corporate Development2
+4 moreStart-upsLife SciencesMergers & AcquisitionsPharmaceutical Industry

From Bali's professional profile.

Deals · 5

Allotera Therapeutics, Inc.Board seat

via Abingworth · filed Jul 2026 · $163M raise

AdvanCellBoard seat

via Abingworth · filed Jul 2026 · $315M raise

press ↗

Spruce BiosciencesBoard seat

via Abingworth · filed Oct 2025 · $50M raise

WugenBoard seat

via Abingworth · filed Jul 2021 · $37.2M raise

Onkure Therapeutics IncBoard seat

via Abingworth · filed Dec 2020 · $94.8M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Led

CymaBay Therapeutics

Board seats

AlloTeraAscendPathalysR1 TxRheumaLogicsValnevaWilson Therapeutics

Investor

Allotera TherapeuticsAnjarium BiosciencesAscend Gene & Cell TherapiesCymaBay TherapeuticsCytospire TherapeuticsGlycomineNuCana BioMedOnboneReneo PharmaceuticalsWilson Therapeutics

Sources: the firm's website · SEC Form D filings · curated public sources.

Colleagues at Abingworth

Alex Asquith
Counsel at Abingworth
Amit Khasgiwala
Investment Professional at Innovatus Capital Partners
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Carlos Paya
Venture Partner at Ysios Capital
David Leathers
General Partner at Abingworth
Dayle Hogg
Operating Executive at Abingworth

Network4

Diya Malhotra
Principal at Abingworth
Jacqueline Grant
Principal at Abingworth
Jayson Punwani
Managing Director, Head of Venture at Abingworth
Ken Haas
Investor at Abingworth

Investors connected to Bali in public investor directories — a warm-intro map.

Frequently asked questions

Who is Bali Muralidhar?
Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.
Where does Bali Muralidhar work?
Bali Muralidhar is Managing Partner at Abingworth and Board director at AdvanCell and Board director at Wugen and Board director at Spruce Biosciences.
What does Bali Muralidhar invest in?
Bali Muralidhar invests in Biotech, Healthtech.
What check size does Bali Muralidhar write?
Bali Muralidhar typically writes checks of $15M – $30M.
What boards does Bali Muralidhar sit on?
Bali Muralidhar holds tracked board seats at AdvanCell, AdvanCell, AlloTera, Allotera Therapeutics, Inc., Ascend, Onkure Therapeutics Inc, Pathalys, R1 Tx, RheumaLogics, Spruce Biosciences.
What companies has Bali Muralidhar invested in?
Investments tracked here include CymaBay Therapeutics, AdvanCell, Allotera Therapeutics, Anjarium Biosciences, Ascend Gene & Cell Therapies, CymaBay Therapeutics, Cytospire Therapeutics, Glycomine, NuCana BioMed, Onbone, Reneo Pharmaceuticals, Spruce Biosciences, and 1 more.
Where did Bali Muralidhar go to school?
Bali Muralidhar studied at University of Cambridge (PhD, Cancer biology); University of Oxford (BMBCh, Clinical medicine); University of Cambridge (MA, Medical Science).
Does Bali Muralidhar lead rounds?
Yes — Bali Muralidhar has led 1 tracked investment.

Same school

Shared employers